288847-35-8

288847-35-8 structure

Name: Oxi 4503
Chemical Name: [3-methoxy-2-phosphonooxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate
CAS Number: 288847-35-8
Molecular Formula: C₁₈H₂₂O₁₂P₂
Molecular Weight: 492.30800
Catalog: Research Areas Cancer
Create Date: 2017-11-21 14:10:55
Modify Date: 2024-01-14 12:31:17
Combretastatin A1 phosphate (Oxi4503; CA1P; Combretastatin A1 diphosphate) is a potent vascular disruptive agent. Combretastatin A1 phosphate exerts anti-angiogenic effects on tumors. Combretastatin A1 phosphate has the potential for the research of pancreatic neuroendocrine tumors[1][2].

Name	[3-methoxy-2-phosphonooxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate
Synonyms	CA1P OXI-4503 UNII-JH6Z94GLUD 1,2-Benzenediol,3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-,1,2-bis(dihydrogen phosphate) Combretastatin A-1 bis(phosphate) Oxi 4503

Description	Combretastatin A1 phosphate (Oxi4503; CA1P; Combretastatin A1 diphosphate) is a potent vascular disruptive agent. Combretastatin A1 phosphate exerts anti-angiogenic effects on tumors. Combretastatin A1 phosphate has the potential for the research of pancreatic neuroendocrine tumors[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
In Vivo	Combretastatin A1 phosphate (100 mg/kg; I.p.; once at day 16 post tumor induction) 显示出抗肿瘤活性，并对小鼠肿瘤发挥抗血管生成作用当与 Sunitinib (HY-10255A) 连用时[2]。 Animal Model: Male CBA mice (CRC liver metastasis)[2] Dosage: 100 mg/kg (received 40 mg/kg of Sunitinib daily from day 14 to 21 post tumor induction) Administration: I.p.; once at day 16 post tumor induction Result: Demonstrated a significantly decreased mean liver weight compared to livers from non tumor bearing animals, significantly reduced tumor vessels.
References	[1]. Patterson DM, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012 Mar 1;18(5):1415-25. [2]. Nguyen L, et al. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis. BMC Cancer. 2016 Jul 26;16:533.